A landmark study published in the latest issue of Nature reveals that a team from Stanford University School of Medicine has achieved a major breakthrough in treating fatal brain disorders. By replacing over half of the diseased microglia in mice with non-genetically matched healthy precursor cells, the team extended the lifespan of mice with Sandhoff disease from 135 days to 250 days, while restoring their motor function and exploratory behavior to nearly normal levels. This marks the first time a “ready-to-use” cell therapy blueprint has been provided for currently untreatable fatal brain diseases like Tay-Sachs and Sandhoff disease.
Tay-Sachs and Sandhoff diseases are part of the lysosomal storage disorders. Affected children lack a key enzyme, leading to the accumulation of metabolic waste in microglia (the brain’s “scavenger cells”) and nearby neurons. They experience rapid degeneration within months of birth and typically die before the age of two. Previous attempts using hematopoietic stem cell transplantation required full-body chemoablation, and healthy cells struggled to cross the blood-brain barrier, resulting in a success rate below 30% along with rejection or graft-versus-host disease risks.
The team adopted a “brain-region specific transplantation” strategy: first, low-dose radiation and drugs were used to temporarily clear existing microglia in the mice’s brains. Then, microglial precursor cells from non-matched donors were directly injected into the ventricles, followed by two approved immunomodulatory drugs to block peripheral immune attacks. Results showed that the new cells accounted for over 85% of total microglia in the brain after 8 months and did not spread to other body parts.
Behavioral tests yielded encouraging results: all untreated diseased mice died by day 135, while all 5 transplanted mice survived until the experiment’s end. They not only ventured into the center of open spaces but also showed significantly better hindlimb grip strength than the control group. Histological analysis found that lysosomal enzymes secreted by donor microglia were taken up by neighboring neurons, suggesting a “cellular outsourcing” mechanism might be key to the therapy’s success.
The breakthrough addresses three major challenges: no need for toxic preconditioning, no gene editing required to supplement the missing enzyme, and avoidance of rejection. The radiation dose, microglia-clearing agents, and immunosuppressants used are already approved for other diseases, enabling rapid potential translation to clinical use. Additionally, the therapy does not rely on the patient’s own cells, holding promise to become an “off-the-shelf product” like blood transfusion, drastically reducing costs and waiting times.
The team notes that common neurodegenerative diseases such as Alzheimer’s and Parkinson’s also involve microglial dysfunction, potentially acting as “slow versions” of lysosomal disorders. If subsequent human trials succeed, beneficiaries could extend beyond rare disease patients to millions suffering from neurodegenerative conditions. Next, the team plans to verify the therapy’s safety in larger animal models closer to humans and discuss early clinical trial designs with the U.S. Food and Drug Administration.
Cell therapy, which aims to replace damaged neurons with healthy transplanted cells or activate endogenous repair mechanisms, offers new hope for treating lysosomal storage disorders and neurodegenerative diseases. For the latter, diseases like Alzheimer’s and ALS still desperately need more effective drugs and therapies. This latest research, with its “brain-region specific transplantation” strategy that avoids systemic toxic preconditioning and rejection, provides a new approach to cell therapy for such conditions. Combined with cutting-edge technologies like gene editing and targeted delivery, cell therapy is expected to play a greater role in related medical fields in the future.
Related topics:
Ribosome Hiccups in Aging Fish Brains May Hold Key to Cellular…
ER Boarding Crisis Worsens: More Patients Wait Days for Beds
Listeria Outbreak Plant Reopens, Raises Fresh Food Safety Concerns
